Top

Journal of Cancer Research and Clinical Oncology

Published in:

16-03-2023 | Multiple Myeloma | Review

Mitochondrial dysfunction and drug targets in multiple myeloma

Authors: Yushan Cui, Fujue Wang, Baijun Fang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Abstract

Multiple myeloma (MM) is the second most common hematological cancer that has no cure. Although currently there are several novel drugs, most MM patients experience drug resistance and disease relapse. The results of previous studies suggest that aberrant mitochondrial function may contribute to tumor progression and drug resistance. Mitochondrial DNA mutations and metabolic reprogramming have been reported in MM patients. Several preclinical and clinical studies have shown encouraging results of mitochondria-targeting therapy in MM patients. In this review, we have summarized our current understanding of mitochondrial biology in MM. More importantly, we have reviewed mitochondrial targeting strategies in MM treatment.

Allen JE, Krigsfeld G, Mayes PA et al (2013) Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 5(171):117r–171r

Allen JE, Krigsfeld G, Patel L et al (2015) Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer 14(1):99PubMedPubMedCentral

Annunziata CM, Davis RE, Demchenko Y et al (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2):115–130PubMedPubMedCentral

Bajpai R, Sharma A, Achreja A et al (2020) Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun 11(1):1228PubMedPubMedCentral

Bellafante E, Morgano A, Salvatore L et al (2014) PGC-1beta promotes enterocyte lifespan and tumorigenesis in the intestine. Proc Natl Acad Sci USA 111(42):E4523–E4531PubMedPubMedCentral

Bengsch B, Johnson AL, Kurachi M et al (2016) Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45(2):358–373PubMedPubMedCentral

Besse L, Besse A, Mendez-Lopez M et al (2019) A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica 104(9):e415–e419PubMedPubMedCentral

Bhalla K, Hwang BJ, Dewi RE et al (2011) PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res 71(21):6888–6898PubMedPubMedCentral

Bisping G, Leo R, Kienast J et al (2003) Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101(7):2775–2783PubMed

Bodet L, Menoret E, Descamps G et al (2010) BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer 103(12):1808–1814PubMedPubMedCentral

Bodet L, Gomez-Bougie P, Touzeau C et al (2011) ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 118(14):3901–3910PubMed

Bolzoni M, Chiu M, Accardi F et al (2016) Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood 128(5):667–679PubMed

Bustany S, Bourgeais J, Tchakarska G et al (2016) Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. Oncotarget 7(29):45214–45224PubMedPubMedCentral

Bustoros M, Sklavenitis-Pistofidis R, Park J et al (2020) Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol 38(21):2380–2389PubMedPubMedCentral

Carracedo A, Cantley LC, Pandolfi PP (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 13(4):227–232PubMedPubMedCentral

Chamoto K, Chowdhury PS, Kumar A et al (2017) Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci USA 114(5):E761–E770PubMedPubMedCentral

Chauhan D, Neri P, Velankar M et al (2007) Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 109(3):1220–1227PubMedPubMedCentral

Chesi M, Mirza NN, Garbitt VM et al (2016) IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med 22(12):1411–1420PubMedPubMedCentral

Chng WJ, Huang GF, Chung TH et al (2011) Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25(6):1026–1035PubMedPubMedCentral

Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464–477PubMed

Czabotar PE, Lessene G, Strasser A et al (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15(1):49–63PubMed

Da SI, de Castro LE, Pedroso AP et al (2020) Biochemical phenotyping of multiple myeloma patients at diagnosis reveals a disorder of mitochondrial complexes I and II and a Hartnup-like disturbance as underlying conditions, also influencing different stages of the disease. Sci Rep 10(1):21836

Dasgupta S, Soudry E, Mukhopadhyay N et al (2012) Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol 227(6):2451–2460PubMedPubMedCentral

Deblois G, Chahrour G, Perry MC et al (2010) Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Res 70(24):10277–10287PubMed

Desplanques G, Giuliani N, Delsignore R et al (2009) Impact of XIAP protein levels on the survival of myeloma cells. Haematologica 94(1):87–93PubMed

Dinndorf PA, Gootenberg J, Cohen MH et al (2007) FDA drug approval summary: pegaspargase (Oncaspar®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12(8):991–998PubMed

Du C, Fang M, Li Y et al (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33–42PubMed

Fan J, Kamphorst JJ, Mathew R et al (2013) Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol 9:712PubMedPubMedCentral

Fink EE, Mannava S, Bagati A et al (2016) Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. Leukemia 30(1):104–111PubMed

Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11(2):109–124PubMed

Gangemi S, Allegra A, Alonci A et al (2012) Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res 61(10):1063–1067PubMed

Gao P, Tchernyshyov I, Chang TC et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762–765PubMedPubMedCentral

Gasparre G, Kurelac I, Capristo M et al (2011) A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Res 71(19):6220–6229PubMed

Gonsalves WI, Ramakrishnan V, Hitosugi T et al (2018) Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. JCI Insight. https://doi.org/10.1172/jci.insight.94543CrossRefPubMedPubMedCentral

Gonsalves WI, Jang JS, Jessen E et al (2020) In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab 8(1):29PubMedPubMedCentral

Graves PR, Aponte-Collazo LJ, Fennell EMJ et al (2019) Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues. ACS Chem Biol 14(5):1020–1029PubMedPubMedCentral

Greer YE, Porat-Shliom N, Nagashima K et al (2018) ONC201 kills breast cancer cells in vitro by targeting mitochondria. Oncotarget 9(26):18454–18479PubMedPubMedCentral

Hartmann FJ, Mrdjen D, McCaffrey E et al (2021) Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol 39(2):186–197PubMed

Hekmatshoar Y, Nakhle J, Galloni M et al (2018) The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance. Biochem J 475(14):2305–2328PubMed

Hoang PH, Cornish AJ, Chubb D et al (2020) Impact of mitochondrial DNA mutations in multiple myeloma. Blood Cancer J 10(5):46PubMedPubMedCentral

Hu Y, Lu W, Chen G et al (2012) K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22(2):399–412PubMed

Huang Y, Si X, Shao M et al (2022) Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol 15(1):38PubMedPubMedCentral

Idelchik MDPS, Begley U, Begley TJ et al (2017) Mitochondrial ROS control of cancer. Semin Cancer Biol 47:57–66PubMed

Ishikawa K, Takenaga K, Akimoto M et al (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320(5876):661–664PubMed

Ishizawa J, Zarabi SF, Davis RE et al (2019) Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell 35(5):721–737PubMedPubMedCentral

Jang JS, Li Y, Mitra AK et al (2019) Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J 9(1):2PubMedPubMedCentral

Jia D, Lu M, Jung KH et al (2019) Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc Natl Acad Sci USA 116(9):3909–3918PubMedPubMedCentral

Joseph NS, Kaufman JL, Dhodapkar MV et al (2020) Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 38(17):1928–1937PubMedPubMedCentral

Katoh M, Nakagama H (2014) FGF receptors: cancer biology and therapeutics. Med Res Rev 34(2):280–300PubMed

Kawano Y, Moschetta M, Manier S et al (2015) Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 263(1):160–172PubMed

Keats JJ, Fonseca R, Chesi M et al (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12(2):131–144PubMedPubMedCentral

Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337PubMed

Kumar S, Kaufman JL, Gasparetto C et al (2017) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 130(22):2401–2409PubMed

Kumar SK, Harrison SJ, Cavo M et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21(12):1630–1642PubMed

Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346(8):564–569PubMed

Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582–2590PubMed

Le A, Lane AN, Hamaker M et al (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110–121PubMedPubMedCentral

Lebleu VS, O’Connell JT, Gonzalez HK et al (2014) PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 16(10):992–1003PubMedPubMedCentral

Lefebvre P, Benomar Y, Staels B (2010) Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 21(11):676–683PubMed

Li F, Wang Y, Zeller KI et al (2005) Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25(14):6225–6234PubMedPubMedCentral

Li W, Qiu S, Chen J et al (2020) Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity 53(2):456–470PubMed

Liu VW, Shi HH, Cheung AN et al (2001) High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res 61(16):5998–6001PubMed

Liu ZG, Tang B, Zeng Y et al (2016) Mitochondrial genome of a spontaneous multiple myeloma bone cancer model mouse C57BL/KaLwRij strain. Mitochondrial DNA A DNA Mapp Seq Anal 27(6):4071–4072PubMed

Maiso P, Huynh D, Moschetta M et al (2015) Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res 75(10):2071–2082PubMedPubMedCentral

Maiuri MC, Kroemer G (2015) Essential role for oxidative phosphorylation in cancer progression. Cell Metab 21(1):11–12PubMed

Marlein CR, Piddock RE, Mistry JJ et al (2019) CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Res 79(9):2285–2297PubMed

Misund K, Keane N, Stein CK et al (2020) MYC dysregulation in the progression of multiple myeloma. Leukemia 34(1):322–326PubMed

Mizutani Y, Nakanishi H, Yamamoto K et al (2005) Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 23(3):448–454PubMed

Mizutani Y, Katsuoka Y, Bonavida B (2010) Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. Int J Oncol 37(2):503–508PubMed

Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417(1):1–13PubMed

Nakagawa Y, Abe S, Kurata M et al (2006) IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 81(11):824–831PubMed

Neri A, Murphy JP, Cro L et al (1989) Ras oncogene mutation in multiple myeloma. J Exp Med 170(5):1715–1725PubMed

Nouri K, Feng Y, Schimmer AD (2020) Mitochondrial ClpP serine protease-biological function and emerging target for cancer therapy. Cell Death Dis 11(10):841PubMedPubMedCentral

Ogando J, Saez ME, Santos J et al (2019) PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) T lymphocytes. J Immunother Cancer 7(1):151PubMedPubMedCentral

Patsoukis N, Bardhan K, Chatterjee P et al (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6:6692PubMed

Petersen CT, Hassan M, Morris AB et al (2018) Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kdelta inhibitors and VIP antagonists. Blood Adv 2(3):210–223PubMedPubMedCentral

Petros JA, Baumann AK, Ruiz-Pesini E et al (2005) mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102(3):719–724PubMedPubMedCentral

Pluta P, Cebula-Obrzut B, Ehemann V et al (2011) Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 58(5):430–435PubMed

Porporato PE, Payen VL, Pérez-Escuredo J et al (2014) A mitochondrial switch promotes tumor metastasis. Cell Rep 8(3):754–766PubMed

Robak P, Drozdz I, Szemraj J et al (2018) Drug resistance in multiple myeloma. Cancer Treat Rev 70:199–208PubMed

Ronca R, Ghedini GC, Maccarinelli F et al (2020) FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. Cancer Res 80(11):2340–2354PubMed

Roth KG, Mambetsariev I, Kulkarni P et al (2020) The mitochondrion as an emerging therapeutic target in cancer. Trends Mol Med 26(1):119–134PubMed

Sabharwal SS, Schumacker PT (2014) Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 14(11):709–721PubMedPubMedCentral

Scarpulla RC, Vega RB, Kelly DP (2012) Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 23(9):459–466PubMedPubMedCentral

Schreier PH, Bankier AT, Roe BA et al (1981) Sequence and organization of the human mitochondrial genome. Nature 290(5806):457–465PubMed

Sedlackova L, Korolchuk VI (2019) Mitochondrial quality control as a key determinant of cell survival. Biochim Biophys Acta Mol Cell Res 1866(4):575–587PubMed

Soncini D, Minetto P, Martinuzzi C et al (2020) Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. Blood Adv 4(18):4312–4326PubMedPubMedCentral

Song IS, Kim HK, Lee SR et al (2013) Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer 133(6):1357–1367PubMed

Soriano GP, Besse L, Li N et al (2016) Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 30(11):2198–2207PubMedPubMedCentral

Sullivan LB, Chandel NS (2014) Mitochondrial reactive oxygen species and cancer. Cancer Metab 2:17PubMedPubMedCentral

Tanaka H, Matsumura I, Ezoe S et al (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9(5):1017–1029PubMed

Thompson RM, Dytfeld D, Reyes L et al (2017) Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget 8(22):35863–35876PubMedPubMedCentral

Touzeau C, Ryan J, Guerriero J et al (2016) BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30(3):761–764PubMed

Tu Y, He J, Liu H et al (2017) The imipridone ONC201 induces apoptosis and overcomes chemotherapy resistance by up-regulation of bim in multiple myeloma. Neoplasia 19(10):772–780PubMedPubMedCentral

Urak R, Walter M, Lim L et al (2017) Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer 5:26PubMedPubMedCentral

Vafa O, Wade M, Kern S et al (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9(5):1031–1044PubMed

van de Donk N, Richardson PG, Malavasi F (2018) CD38 antibodies in multiple myeloma: back to the future. Blood 131(1):13–29PubMed

van de Donk N, Pawlyn C, Yong KL (2021a) Multiple myeloma. Lancet 397(10272):410–427PubMed

van de Donk NWCJ, Usmani SZ, Yong K (2021b) CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol 8(6):e446–e461PubMed

van Gisbergen MW, Voets AM, Starmans MH et al (2015) How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutat Res Rev Mutat Res 764:16–30PubMed

Vardhana SA, Hwee MA, Berisa M et al (2020) Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol 21(9):1022–1033PubMedPubMedCentral

Villena JA (2015) New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J 282(4):647–672PubMed

Wang Q, Zhao D, Xian M et al (2020) MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood 136(22):2557–2573PubMedPubMedCentral

Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35(8):427–433PubMedPubMedCentral

Wise DR, Deberardinis RJ, Mancuso A et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105(48):18782–18787PubMedPubMedCentral

Xiang Y, Fang B, Liu Y et al (2020) SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation. Life Sci 256:117971PubMed

Yu M, Wan Y, Zou Q (2010) Decreased copy number of mitochondrial DNA in Ewing’s sarcoma. Clin Chim Acta 411(9–10):679–683PubMed

Yu Y, Imrichova H, Wang H et al (2020) Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion. Nat Immunol 21(12):1540PubMed

Zhan X, Yu W, Franqui-Machin R et al (2017) Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. Oncotarget 8(67):111213–111224PubMedPubMedCentral

Zhang H, Li L, Chen Q et al (2018) PGC1beta regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Mol Oncol 12(9):1579–1595PubMedPubMedCentral

Zheng W, O’Hear CE, Alli R et al (2018) PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32(5):1157–1167PubMedPubMedCentral

Zhou L, Zhang Y, Leng Y et al (2019) The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. J Hematol Oncol 12(1):25PubMedPubMedCentral

Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313(3):459–465PubMed

Title: Mitochondrial dysfunction and drug targets in multiple myeloma
Authors: Yushan Cui
Fujue Wang
Baijun Fang
Publication date: 16-03-2023
Publisher: Springer Berlin Heidelberg
Keyword: Multiple Myeloma
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-04672-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2023

Improved exosome isolation methods from non-small lung cancer cells (NC1975) and their characterization using morphological and surface protein biomarker methods

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study

Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database

The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis

Extracapsular extension of transitional zone prostate cancer miss-detected by multiparametric magnetic resonance imaging

Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials